Literature DB >> 9020879

Reduced very-low-density lipoprotein fractional catabolic rate in apolipoprotein C1-deficient mice.

M C Jong1, J H van Ree, V E Dahlmans, R R Frants, M H Hofker, L M Havekes.   

Abstract

The function of apolipoprotein (apo) C1 in vivo is not clearly defined. Because transgenic mice overexpressing human apoC1 show elevated triacylglycerol (TG) levels [Simonet, Bucay, Pitas, Lauer and Taylor (1991) J. Biol. Chem. 266, 8651-8654], an as yet unknown role for apoC1 in TG metabolism has been suggested. Here we investigated directly the effect of the complete absence of apoC1 on very-low-density lipoprotein (VLDL)-TG lipolysis, clearance and production, by performing studies with the previously generated apoC1-deficient mice. On a sucrose-rich, low fat/low cholesterol (LFC) diet, apoC1-deficient mice accumulate in their circulation VLDL particles, which contain relatively lower amounts of lipids when compared with VLDL isolated from control mice. Lipolysis assays in vitro on VLDL from apoC1-deficient and control mice showed no differences in apparent K(m) and Vmax values (0.27 +/- 0.06 versus 0.24 +/- 0.03 mmol of TG/litre and 0.40 +/- 0.03 versus 0.36 +/- 0.03 mmol of non-esterified fatty acid (NEFA)/min per litre respectively). To correct for potential differences in the size of the VLDL particles, the resulting K(m) values were also expressed relative to apoB concentration. Under these conditions apoC1-deficient VLDL displayed a lower, but not significant, K(m) value when compared with control VLDL (3.44 +/- 0.71 versus 4.44 +/- 0.52 mmol of TG2/g apoB per litre). VLDL turnover studies with autologous injections of [3H]TG-VLDL in vivo showed that the VLDL fractional catabolic rate (FCR) was decreased by up to 50% in the apoC1-deficient mice when compared with control mice (10.5 +/- 3.4 versus 21.0 +/- 1.2/h of pool TG). No significant differences between apoC1-deficient and control mice were observed in the hepatic VLDL production estimated by Triton WR139 injections (0.19 +/- 0.02 versus 0.21 +/- 0.05 mmol/h of TG per kg) and in the extra-hepatic lipolysis of VLDL-TG (4.99 +/- 1.62 versus 3.46 +/- 1.52/h of pool TG) in vivo. Furthermore, [125I]VLDL-apoB turnover experiments in vivo also showed a 50% decrease in the FCR of VLDL in apoC1-deficient mice when compared with control mice on the LFC diet (1.1 +/- 0.3 versus 2.1 +/- 0.1/h of pool apoB). When mice were fed a very high fat/high cholesterol (HFC) diet, the VLDL-apoB FCR was further decreased in apoC1-deficient mice (0.4 +/- 0.1 versus 1.4 +/- 0.4/h of pool apoB). We conclude that, in apoC1-deficient mice, the FCR of VLDL is reduced because of impaired uptake of VLDL remnants by hepatic receptors, whereas the production and lipolysis of VLDL-TG is not affected.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9020879      PMCID: PMC1218089          DOI: 10.1042/bj3210445

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  25 in total

1.  Comparison between the use of isopropanol and tetramethylurea for the solubilisation and quantitation of human serum very low density apolipoproteins.

Authors:  L Holmquist; K Carlson; L A Carlson
Journal:  Anal Biochem       Date:  1978-08-01       Impact factor: 3.365

2.  Thf complete amino acid sequence of C-I (apoLp-Ser), an apolipoprotein from human very low density lipoproteins.

Authors:  R S Shulman; P N Herbert; K Wehrly; D S Fredrickson
Journal:  J Biol Chem       Date:  1975-01-10       Impact factor: 5.157

3.  Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein.

Authors:  K H Weisgraber; R W Mahley; R C Kowal; J Herz; J L Goldstein; M S Brown
Journal:  J Biol Chem       Date:  1990-12-25       Impact factor: 5.157

4.  Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources.

Authors:  R J Havel; C J Fielding; T Olivecrona; V G Shore; P E Fielding; T Egelrud
Journal:  Biochemistry       Date:  1973-04-24       Impact factor: 3.162

5.  The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat.

Authors:  S H Quarfordt; G Michalopoulos; B Schirmer
Journal:  J Biol Chem       Date:  1982-12-25       Impact factor: 5.157

6.  Synthetic low and high fat diets for the study of atherosclerosis in the mouse.

Authors:  P M Nishina; J Verstuyft; B Paigen
Journal:  J Lipid Res       Date:  1990-05       Impact factor: 5.922

7.  Delayed clearance of very low density and intermediate density lipoproteins with enhanced conversion to low density lipoprotein in WHHL rabbits.

Authors:  T Kita; M S Brown; D W Bilheimer; J L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

8.  The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E.

Authors:  E E Windler; P T Kovanen; Y S Chao; M S Brown; R J Havel; J L Goldstein
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

9.  Two copies of the human apolipoprotein C-I gene are linked closely to the apolipoprotein E gene.

Authors:  S J Lauer; D Walker; N A Elshourbagy; C A Reardon; B Levy-Wilson; J M Taylor
Journal:  J Biol Chem       Date:  1988-05-25       Impact factor: 5.157

10.  Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver.

Authors:  E Windler; R J Havel
Journal:  J Lipid Res       Date:  1985-05       Impact factor: 5.922

View more
  10 in total

1.  Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet.

Authors:  Janna A van Diepen; Irene O C M Vroegrijk; Jimmy F P Berbée; Steven E Shoelson; Johannes A Romijn; Louis M Havekes; Patrick C N Rensen; Peter J Voshol
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-08-23       Impact factor: 4.310

Review 2.  Hyperlipidaemia and cardioprotection: Animal models for translational studies.

Authors:  Ioanna Andreadou; Rainer Schulz; Lina Badimon; Adriana Adameová; Petra Kleinbongard; Sandrine Lecour; Panagiota-Efstathia Nikolaou; Ines Falcão-Pires; Gemma Vilahur; Nicholas Woudberg; Gerd Heusch; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2020-01-17       Impact factor: 8.739

3.  Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1.

Authors:  M C Jong; M J Gijbels; V E Dahlmans; P J Gorp; S J Koopman; M Ponec; M H Hofker; L M Havekes
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

4.  Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.

Authors:  M C Jong; K W van Dijk; V E Dahlmans; H Van der Boom; K Kobayashi; K Oka; G Siest; L Chan; M H Hofker; L M Havekes
Journal:  Biochem J       Date:  1999-03-01       Impact factor: 3.857

5.  APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians.

Authors:  Piya Lahiry; Henian Cao; Matthew R Ban; Rebecca L Pollex; Mary Mamakeesick; Bernard Zinman; Stewart B Harris; Anthony J G Hanley; Murray W Huff; Philip W Connelly; Robert A Hegele
Journal:  J Lipid Res       Date:  2009-10-06       Impact factor: 5.922

6.  Pharmacodynamics and pharmacogenomics of diverse receptor-mediated effects of methylprednisolone in rats using microarray analysis.

Authors:  Richard R Almon; Debra C DuBois; Emily H Brandenburg; Wei Shi; Shuzhong Zhang; Robert M Straubinger; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-04       Impact factor: 2.745

7.  The apolipoprotein C-I content of very-low-density lipoproteins is associated with fasting triglycerides, postprandial lipemia, and carotid atherosclerosis.

Authors:  John-Bjarne Hansen; José A Fernández; Ann-Trude With Notø; Hiroshi Deguchi; Johan Björkegren; Ellisiv B Mathiesen
Journal:  J Lipids       Date:  2011-07-06

Review 8.  Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia.

Authors:  L Renee Ruhaak; Arnoud van der Laarse; Christa M Cobbaert
Journal:  Ann Clin Biochem       Date:  2019-03-19       Impact factor: 2.057

9.  Fatty acid-inducible ANGPTL4 governs lipid metabolic response to exercise.

Authors:  Milène Catoire; Sheril Alex; Nicolas Paraskevopulos; Frits Mattijssen; Inkie Evers-van Gogh; Gert Schaart; Jacob Jeppesen; Anita Kneppers; Marco Mensink; Peter J Voshol; Gunilla Olivecrona; Nguan Soon Tan; Matthijs K C Hesselink; Jimmy F Berbée; Patrick C N Rensen; Eric Kalkhoven; Patrick Schrauwen; Sander Kersten
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-03       Impact factor: 11.205

Review 10.  Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models.

Authors:  Debapriya Basu; Karin E Bornfeldt
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-06       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.